Results 21 to 30 of about 2,076,500 (256)

Immunogenicity and Efficacy of A/H1N1pdm Vaccine Among Subjects With Severe Motor and Intellectual Disability in the 2010/11 Influenza Season

Journal of Epidemiology, 2016
Background: While the immunogenicity and effectiveness of seasonal influenza vaccines among subjects with severe motor and intellectual disability (SMID) are known to be diminished, the efficacy of the A/H1N1pdm vaccine has not been evaluated.
Megumi Hara
doaj   +1 more source

Effectiveness of influenza vaccine in aging and older adults: comprehensive analysis of the evidence [PDF]

, 2012
Foremost amongst the diseases preventable by vaccination is influenza. Worldwide, influenza virus infection is associated with serious adverse events leading to hospitalization, debilitating complications, and death in elderly individuals ...
Assir N, Lang, Pierre-Olivier, Govind, Sheila, Aspinall R, Mendes A, Mendes, Aline, Socquet, Jennifer, Govind S, Socquet J, Assir, Noémie, Lang PO, Aspinall, Richard   +11 more
core   +1 more source

Correlates of malaria vaccine efficacy [PDF]

, 2021
Contains fulltext : 238206.pdf (Publisher’s version ) (Open Access)Introduction: An effective vaccine against malaria forms a global health priority.
Stanisic, D.I., Stanisic, Danielle I, McCall, Matthew BB, McCall, M.B.B.   +3 more
core   +1 more source

Design of a phase III multicenter trial to evaluate the efficacy of the RTS,S/AS01 malaria vaccine in children across diverse transmission settings in Africa. [PDF]

, 2011
BACKGROUND\ud \ud GlaxoSmithKline Biologicals and the PATH Malaria Vaccine Initiative are working in partnership to develop a malaria vaccine to protect infants and children living in malaria endemic regions of sub-Saharan Africa, which can be delivered ...
Amanda Leach, Vekemans Johan, Savarese Barbara, Abdulla, Salim, Loucq, Christian, Salim Abdulla, Cahill Conor, Owusu-Agyei, Seth, Macete, Eusebio, Lievens Marc, Njuguna, Patricia, Marc Lievens, Christian Loucq, Ofori-Anyinam Opokua, Leach, Amanda, Njuguna Patricia, Vekemans, Johan, Patricia Njuguna, Cahill, Conor, Macete Eusebio, Barbara Savarese, Savarese, Barbara, Seth Owusu-Agyei, Owusu-Agyei Seth, Opokua Ofori-Anyinam, Ballou, W Ripley, Abdulla Salim, Clinical Trials Partnership Committee, Lievens, Marc, Ofori-Anyinam, Opokua, null null, Leach Amanda, Eusebio Macete, Conor Cahill, Ballou W Ripley, Loucq Christian, Johan Vekemans, W Ripley Ballou   +37 more
core   +1 more source

Assessment of Safety and Prophylactic Efficacy of the EpiVacCorona Peptide Vaccine for COVID-19 Prevention (Phase III)

Vaccines, 2023
The State Research Center of Virology and Biotechnology “VECTOR” of the Federal Service for the Oversight of Consumer Protection and Welfare (Rospotrebnadzor) has developed the peptide-based EpiVacCorona vaccine, which is the first synthetic peptide ...
Alexander B. Ryzhikov, Evgeny A. Ryzhikov, Marina P. Bogryantseva, Svetlana V. Usova, Elena A. Nechaeva, Elena D. Danilenko, Stepan A. Pyankov, Andrey S. Gudymo, Anastasiya A. Moiseeva, Galina S. Onkhonova, Oleg V. Pyankov, Ekaterina S. Sleptsova, Nikita V. Lomakin, Veronika S. Vasilyeva, Mikhail V. Tulikov, Vitaly G. Gusarov, Andrey A. Pulin, Maria A. Balalaeva, Svetlana B. Erofeeva, Stanislav A. Terpigorev, Olga A. Rychkova, Ivan M. Petrov, Viktoriia Y. Delian, Vladimir V. Rafalskiy, Sergey V. Tyranovets, Elena V. Gavrilova, Rinat A. Maksyutov   +26 more
doaj   +1 more source

The effect of immunization schedule with the malaria vaccine candidate RTS,S/AS01E on protective efficacy and anti-circumsporozoite protein antibody avidity in African infants [PDF]

, 2015
The malaria vaccine RTS,S induces antibodies against the Plasmodium falciparum circumsporozoite protein (CSP) and the concentration of Immunoglobulin G (IgG) against the repeat region of CSP following vaccination is associated with protection from P ...
Mpina, Maxmilliam, Ajua, Anthony, Abdulla, Salim, Jongert, Erik, Cambron, Pierre, Ockenhouse, Chris F., Agnandji, Selidji Todagbe, Asante, Kwaku Poku, Owusu-Agyei, Seth, Mwangoka, Grace, Kremsner, Peter G., Lell, Bertrand, Mordmüller, Benjamin, Salim, Nahya, Lievens, Marc, Ockenhouse, Chris F, Kremsner, Peter G, Vekemans, Johan, Tanner, Marcel   +18 more
core   +1 more source

Safety and immunogenicity of RTS,S/AS02D malaria vaccine in infants. [PDF]

, 2008
BACKGROUND: The RTS,S/AS malaria vaccine is being developed for delivery through the World Health Organization's Expanded Program on Immunization (EPI).
Machera, Francisca, Membi, Christopher, Kubhoja, Sulende, Cohen, Joe, Abdulla, Salim, Aebi, Thomas, Oberholzer, Rolf, Omari, Said, Ballou, W Ripley, Jumanne, Ajuza, Schellenberg, David M, Dubois, Marie-Claude, Salim, Nahya, Lievens, Marc, Carter, Terrell, Shomari, Mwanjaa, Urassa, Alwisa, Juma, Omar, Leach, Amanda, Demoitié, Marie-Ange, Vekemans, Johan, Mshinda, Hassan, Villafana, Tonya, Tanner, Marcel   +23 more
core   +1 more source

Vaccine efficacy—the biggest challenge today [PDF]

Exploration of Immunology
The efficacy of viral vector-based vaccines is essential to provide long-term protection and prevention of emerging epidemics and pandemics in parallel to other vaccine platforms.
Kenneth Lundstrom
doaj   +1 more source

Dengvaxia: the world’s first vaccine for prevention of secondary dengue

Therapeutic Advances in Vaccines and Immunotherapy, 2021
The objective of this manuscript was to review and evaluate the efficacy and safety data of Dengvaxia for the treatment of severe secondary dengue infection. Dengvaxia is the brand name for chimeric yellow fever-dengue-tetravalent dengue vaccine (CYD-TDV)
Danielle Tully, Carrie L. Griffiths
doaj   +1 more source

The time-course of protection of the RTS,S vaccine against malaria infections and clinical disease [PDF]

, 2015
Recent publications have reported follow-up of the RTS,S/AS01 malaria vaccine candidate Phase III trials at 11 African sites for 32 months (or longer).
Peter Pemberton-Ross, Melissa A. Penny, Smith, Thomas A., Thomas A. Smith, Pemberton-Ross, Peter, Penny, Melissa A.   +5 more
core   +1 more source